文献速递肾移植肾小球疾病

美国多发性骨髓瘤与淀粉样变性患者肾移植结局

Outcomes of kidney transplantation in patients with myeloma and amyloidosis in the USA.
PubMed 文献 · Nephrol Dial Transplant · 2022-01-01

基于美国器官共享联合网络/器官获取与移植网络2006—2018年数据的回顾性研究,比较因浆细胞病所致终末期肾病与其他原因行首次肾移植的成人受者。浆细胞病组患者及移植物生存均劣于非浆细胞病组;淀粉样变性组更差,多发性骨髓瘤组无统计学差异。

要点

  • 浆细胞病所致终末期肾病肾移植受者,活体与尸体供肾患者生存均劣于非浆细胞病组。
  • 浆细胞病组移植物生存亦劣于非浆细胞病组,活体与尸体供肾均如此。
  • 淀粉样变性组患者及移植物生存更差,多发性骨髓瘤组与非浆细胞病组无统计学差异。

核心结论

  • 研究数据对确定浆细胞病患者肾移植资格及讨论移植风险至关重要。

研究设计与样本

  • 回顾性研究,使用美国器官共享联合网络/器官获取与移植网络2006—2018年数据,比较因浆细胞病所致终末期肾病与其他原因行首次肾移植的成人受者。
  • 共纳入168 369例成人首次肾移植受者,每年0.22—0.43%以浆细胞病为终末期肾病病因。

主要发现

  • 活体供肾中,浆细胞病组患者生存劣于非浆细胞病组,aHR 2.24(95%CI 1.67—2.99);尸体供肾中aHR 1.40(95%CI 1.08—1.83)。
  • 活体供肾中,浆细胞病组患者生存劣于糖尿病组,aHR 1.87(95%CI 1.37—2.53)vs aHR 1.16(95%CI 0.89—1.2)。
  • 活体供肾中,浆细胞病组移植物生存劣于非浆细胞病组,aHR 1.72(95%CI 1.91—2.56);尸体供肾中aHR 1.30(95%CI 1.03—1.66)。
  • 淀粉样变性组患者及移植物生存更差;多发性骨髓瘤组与非浆细胞病组无统计学差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent improvement in treatment and patient survival has opened the eligibility of kidney transplantation to patients who developed end-stage kidney disease (ESKD) from plasma cell dyscrasias (PCDs). Data on clinical outcomes in this population are lacking. METHODS: We conducted a retrospective study of United Network for Organ Sharing/Organ Procurement and Transplantation Network dataset (2006-2018) to compare patient and graft outcomes of kidney transplant recipients with ESKD due to PCD versus other causes. RESULTS: Among 168 369 adult first kidney transplant recipients, 0.22-0.43% per year had PCD as the cause of ESKD. The PCD group had worse survival than the non-PCD group for both living and deceased donor types {adjusted hazard ratio [aHR] 2.24 [95% confidence interval (CI) 1.67-2.99] and aHR 1.40 [95% CI 1.08-1.83], respectively}. The PCD group had worse survival than the diabetes group, but only among living donors [aHR 1.87 (95% CI 1.37-2.53) versus aHR 1.16 (95% CI 0.89-1.2)]. Graft survival in patients with PCD were worse than non-PCD in both living and deceased donors [aHR 1.72 (95% CI 1.91-2.56) and aHR 1.30 (95% CI 1.03-1.66)]. Patient and graft survival were worse in amyloidosis but not statistically different in multiple myeloma compared with the non-PCD group. CONCLUSION: The study data are crucial when determining kidney transplant eligibility and when discussing transplant risks in patients with PCD.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Ng JH, Izard S, Murakami N, et al. Outcomes of kidney transplantation in patients with myeloma and amyloidosis in the USA. Nephrol Dial Transplant. 2022. PMID: 35687020. doi:10.1093/ndt/gfac196

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。